Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Delphine HequetN HajjajiE Charafe-JauffretA BoucrautaF DalencV NicolaiJ LopezO TredanElise DelucheV FermeauxL TixierA CayreE MenetF LereboursR RouzierPublished in: Cancer medicine (2023)
The use of genomic testing proved cost-saving in this large multicentric real-life analysis, even in certain cases when the test was performed outside recommendations.